A Study of LY3305677 in Healthy Participants

NCT02972645 · Completed

Last updated 2026-05-28

This clinical trial tests the safety of the investigational drug LY3305677 in healthy adult participants by monitoring for any serious side effects.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 66 people

Who can join Ages 20–65 · all sexes Healthy volunteers accepted.

Timeline Started 2016-12 · est. completion 2017-07

Where 1 site · United Kingdom

What this study is testing ClinicalTrials.gov NCT02972645 ↗

Description as written by the study sponsor.

The purpose of this study is to evaluate the safety of LY3305677 and any side effects that might be associated with it. This study will also look at how much LY3305677 gets into the blood stream, how long it takes the body to remove it. This study involves a single dose of LY3305677 administered by subcutaneous injection (SC). Participation in this study is expected to last up to 16 weeks.

Treatments tested

LY3305677 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Number of Participants with One or More Serious Adverse Event(s) (SAEs) considered by the Investigator to be Related to Study Drug Administration
Sponsor	Eli Lilly and Company
Conditions studied	Healthy
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02972645 ↗